Overview
Lanreotide (brand: Somatuline) is an FDA-approved synthetic octapeptide analog of somatostatin indicated for acromegaly, neuroendocrine tumors (NETs), and carcinoid syndrome. Its long-acting depot formulation allows once-monthly subcutaneous injection, improving adherence compared to octreotide. Approved by the FDA in 2007.
Mechanism of action
Lanreotide binds with high affinity to somatostatin receptor subtypes SSTR2 and SSTR5 on pituitary somatotropes and NET cells. SSTR2 activation inhibits adenylyl cyclase and reduces cAMP, suppressing GH and IGF-1 secretion. SSTR5 binding contributes to antisecretory effects in carcinoid and pancreatic NETs. Compared to native somatostatin, lanreotide has substantially greater receptor affinity and a half-life of approximately 23–30 days in the Autogel/Depot formulation due to self-assembling nanotubes.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| acromegaly | subcutaneous | 60–120 mg | every 4 weeks | Start at 90 mg q4w for 3 months; adjust based on GH and IGF-1 levels |
| GEP-NET / carcinoid | subcutaneous | 120–120 mg | every 4 weeks |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Phase III trials (CLARINET, LANSCAPE) demonstrated lanreotide significantly extends progression-free survival in gastroenteropancreatic NETs and controls GH/IGF-1 in acromegaly. The CLARINET trial (2014) was landmark: lanreotide reduced the risk of progression or death by 47% in GEP-NETs. Approved indications include acromegaly, GEP-NETs, and carcinoid syndrome. Post-marketing data support long-term safety over 10+ years of use.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Lanreotide for synergistic effects.
Legal status
FDA-approved (NDA 022074, August 2007) for acromegaly and GEP-NETs. Available as Somatuline Depot (US) and Somatuline Autogel (EU). Prescription-only; administered by healthcare professional.
Where to get it
Prescription required
Lanreotide is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.